Polymer: bioceramic composites optimization by tetracycline addition.

The aim of this study was to evaluate the biocompatibility of composites of poly-lactic acid polymer (PLA) and copolymer of lactic and glycolic acid (PLGA), dispersed in a bioceramic matrix, Osteosynt (BC), to which tetracycline (TC) was added. The in vitro test used direct contact test (ASTM F-813) and elution test (USP-XXIII, ISO 10993-5), and in vivo evaluation was performed after subcutaneous implantation in outbread Swiss mice. The 0.01% (w/w) TC addition did not affect composite cytotoxicity in vitro. The macroscopic and histologic evaluation in vivo after 1, 7, 13, 21, 28 and 56 days showed an initial intense infiltrate of inflammatory cells for most of the groups. The tissue showed normal pattern after 21 days for all the groups. TC addition exhibited significantly larger reduction of inflammation signs (Mann-Whitney test, p<0.05) in the critical period of the resolution of the inflammatory process. Angiogenesis, cellular adsorption and fibrous deposit were observed on SEM evaluation. In conclusion, TC addition optimized composites polymer/bioceramic biocompatibility, contributing to anti-inflammatory response during the early phases of the wound healing process.

[1]  R. Yukna,et al.  Bone and bone substitutes. , 1999, Periodontology 2000.

[2]  R. Genco,et al.  A biochemical approach to periodontal regeneration: tetracycline treatment conditions dentin surfaces. , 1986, Journal of periodontal research.

[3]  D. Uskoković,et al.  Synthesis and application of hydroxyapatite/polylactide composite biomaterial , 2004 .

[4]  A. Pataro,et al.  Surface effects and desorption of tetracycline supramolecular complex on bovine dentine. , 2003, Biomaterials.

[5]  S. Koujak,et al.  Minocycline inhibits antigen processing for presentation to human T cells: additive inhibition with chloroquine at therapeutic concentrations. , 2004, Clinical immunology.

[6]  R Borojevic,et al.  Characterization of a bovine collagen-hydroxyapatite composite scaffold for bone tissue engineering. , 2003, Biomaterials.

[7]  R. Seymour,et al.  Tetracyclines in the management of periodontal diseases. A review. , 2005, Journal of clinical periodontology.

[8]  F. Lin,et al.  Biological effects and cytotoxicity of the composite composed by tricalcium phosphate and glutaraldehyde cross-linked gelatin. , 1998, Biomaterials.

[9]  P. Vadas,et al.  Inhibition of enzymatic activity of phospholipases A2 by minocycline and doxycycline. , 1992, Biochemical pharmacology.

[10]  H. Lin,et al.  Effect of minocycline on prostaglandin formation in gingival fibroblasts. , 1988, Journal of periodontal research.

[11]  K. Burg,et al.  Biomaterial developments for bone tissue engineering. , 2000, Biomaterials.

[12]  J. M. Goodson.  Pharmacokinetic principles controlling efficacy of oral therapy , 1989 .

[13]  C. Lowenstein,et al.  Post‐transcriptional regulation of inducible nitric oxide synthase mRNA in murine macrophages by doxycycline and chemically modified tetracyclines , 1997, FEBS letters.

[14]  D van Steenberghe,et al.  The use of tetracycline-containing controlled-release fibers in the treatment of refractory periodontitis. , 1997, Journal of periodontology.

[15]  J O Hollinger,et al.  Biodegradable bone repair materials. Synthetic polymers and ceramics. , 1986, Clinical orthopaedics and related research.

[16]  A. Nakajima,et al.  Preparation and properties of porous alumina ceramics with uni-directionally oriented pores by extrusion method using a plastic substance as a pore former , 2007 .

[17]  A. Ferrante,et al.  Inhibition of mitogen-induced human lymphocyte proliferative responses by tetracycline analogues. , 1979, Clinical and experimental immunology.

[18]  N. Esterly,et al.  The effect of antimicrobial agents on leukocyte chemotaxis. , 1978, The Journal of investigative dermatology.

[19]  I. Duncan,et al.  Inhibition of autoimmune encephalomyelitis by a tetracycline , 2002, Annals of neurology.

[20]  David J. Mooney,et al.  Synthesis and Properties of Biodegradable Polymers Used as Synthetic Matrices for Tissue Engineering , 1997 .

[21]  C. M. Agrawal,et al.  Sterilization, toxicity, biocompatibility and clinical applications of polylactic acid/polyglycolic acid copolymers. , 1996, Biomaterials.

[22]  C. Nastruzzi,et al.  Biodegradable microparticles for sustained delivery of tetracycline to the periodontal pocket: formulatory and drug release studies. , 1997, Journal of microencapsulation.

[23]  Minocycline in active rheumatoid arthritis , 1994 .

[24]  L L Hench,et al.  Biomaterials: a forecast for the future. , 1998, Biomaterials.

[25]  R. Couch,et al.  Effects of tetracycline on leukotaxis. , 1974, The Journal of infectious diseases.

[26]  J. Brotchi,et al.  Minocycline-induced activation of tetracycline-responsive promoter , 2003, Neuroscience Letters.

[27]  D. Uskoković,et al.  Biphasic calcium phosphate coated with poly-d,l-lactide-co-glycolide biomaterial as a bone substitute , 2007 .

[28]  A. Kirkbride,et al.  SINTERED POROUS HYDROXYAPATITES WITH INTRINSIC OSTEOINDUCTIVE ACTIVITY: GEOMETRIC INDUCTION OF BONE FORMATION , 1999 .

[29]  Y. Shikinami,et al.  Bioresorbable devices made of forged composites of hydroxyapatite (HA) particles and poly-L-lactide (PLLA): Part I. Basic characteristics. , 1999, Biomaterials.

[30]  L. Golub,et al.  Potential of tetracyclines to modify cartilage breakdown in osteoarthritis. , 1996, Current opinion in rheumatology.

[31]  J. Gardin,et al.  Minocycline inhibits caspase activation and reactivation, increases the ratio of XIAP to smac/DIABLO, and reduces the mitochondrial leakage of cytochrome C and smac/DIABLO. , 2004, Journal of the American College of Cardiology.

[32]  R. Fleischmajer,et al.  Tetracyclines: nonantibiotic properties and their clinical implications. , 2006, Journal of the American Academy of Dermatology.

[33]  V. Yong,et al.  Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis. , 2002, Brain : a journal of neurology.